What is a precision medicine?
- Whilst conventional CF treatments target the symptoms, precision medicines tackle the underlying genetic mutations which cause the condition.
- Precision medicines are so called because they only treat certain mutations. These drugs are part of a wider move towards personalised healthcare.
Which precision medicines treat cystic fibrosis?
Three precision medicines that help to treat the underlying cause of cystic fibrosis have been licensed for use in the UK, while others are currently being tested on people with CF to determine how they work.
Orkambi (ivacaftor/lumacaftor) targets a mutation that around 50% of people with cystic fibrosis in the UK have. Find out more about the drug and its availability here.
Symkevi (a combination of ivacaftor and tezacaftor) targets multiple mutation combinations that approximately 55% of the UK CF population have. Find out more about the drug and its availability here.
Kaftrio (triple combination therapy)
The triple combination therapy, Kaftrio, (brand name Trikafta in the United States) uses a combination of ivacaftor, tezacaftor and elexacaftor, and targets mutations that approximately 90% of the CF population have. Find out more about the drug and its availability here.
Kalydeco (ivacaftor) targets mutations that under 10% of people with CF in the UK have. Find out more about the drug and its availability here.
How are we campaigning for access to these drugs?
The Trust has been campaigning hard to ensure that people with CF can access all CFTR modulators. Find out more about the work we're doing to extend access to precision medicines by signing up to our campaigner newsletter or exploring our campaign timeline and latest policy and campaigning news.
Take a look at the list of parliamentarians who have supported our campaign for access to life-saving drugs.